Side-by-side · Research reference

ProstamaxvsSermorelin

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED11/38 cited

BPhase 3HUMAN-REVIEWED14/43 cited

Prostamax

Khavinson Bioregulator · Tissue-Specific Peptide

0.05 ng/mLActive concentrationZakutskiĭ 2006

2.5×SCE frequency increaseDzhokhadze 2012

4 AAPeptide length

SQ · Protocol per Khavinson tradition

Sermorelin

GHRH 1-29 fragment · Short-acting

100–500 mcgPer doseMolteno 2013

Phase 3Evidence levelWalker 1994 Molteno 2013

~12 minHalf-lifeMolteno 2013

SQ · Pre-sleep · 1×/day

01Mechanism of Action

Parameter

Prostamax

Sermorelin

Primary target

Chromatin in prostatic cells — pericentromeric heterochromatin regions

Pituitary GHRH receptorWalker 1994

Pathway

Epigenetic modulation → heterochromatin decondensation → transcriptional derepressionDzhokhadze 2012

GHRH-R → Gαs → cAMP → PKA → GH vesicle exocytosisWalker 1994

Downstream effect

Increased sister chromatid exchange, Ag-NOR activation, reduced C-heterochromatin condensation; tissue-specific regenerative stimulation in prostate organotypic culturesDzhokhadze 2012 Zakutskiĭ 2006

Pulsatile GH release; subsequent IGF-1 elevationMolteno 2013

Feedback intact?

—

Yes — short pulse preserves feedback

Origin

Synthetic tetrapeptide modeled on naturally occurring protein-derived bioregulators isolated between lysine-arginine motifs in long-lived speciesKhavinson 2017

Unmodified active 29-AA fragment of human GHRH (1-44)Walker 1994

Antibody development

—

02Dosage Protocols

Parameter

Prostamax

Sermorelin

Effective concentration (in vitro)

0.05 ng/mLZakutskiĭ 2006

Organotypic culture model; demonstrated tissue-specific stimulation.

—

Human clinical dose

Not established

No published human trials; dosing extrapolated from Russian clinical tradition (not peer-reviewed).

—

Evidence basis

Animal / organotypic cultureZakutskiĭ 2006 Dzhokhadze 2012

No randomized controlled trials in humans.

Phase 3 (Geref pediatric); clinical practiceWalker 1994 Molteno 2013

Age groups studied

Young (3-week) and aged (18-month) rats; elderly humans (75–86 years) in vitroZakutskiĭ 2006 Dzhokhadze 2012

—

Duration

Not specified

Khavinson protocols typically 10–20 days per cycle; no long-term safety data.

8–12 weeks per cycle

Standard dose

—

100–500 mcg per injectionMolteno 2013

Frequency

—

Once daily, pre-sleep

Lower / starter dose

—

100 mcg per dose

Reconstitution

—

Bacteriostatic water

Timing

—

Pre-sleep, fasted preferred

Half-life

—

~12 min (plasma)Molteno 2013

Shorter than tesamorelin (~26 min) — simpler GHRH analogue.

04Side Effects & Safety

Parameter

Prostamax

Sermorelin

Published adverse events

None reported in available literature

—

Genotoxicity signals

Increased sister chromatid exchange (SCE) — marker of DNA recombination/repair; unclear long-term implications

—

Metal ion interactions

Modulates Cu(II) and Cd(II) chromatin effects; unknown clinical relevance

—

Human safety data

Absent — no published Phase 1/2/3 trials

—

Injection site reaction

—

Mild erythema, transient pain

Flushing / headache

—

Common transient effect

IGF-1 elevation

—

Modest at standard doses

Cancer risk

—

Contraindicated in active malignancy (GH/IGF-1 axis)

Pregnancy / OB

—

Avoid

Glucose handling

—

Generally neutral

Absolute Contraindications

Prostamax

·Active prostate malignancy — epigenetic modulation effects unknown in cancer

Sermorelin

·Active malignancy
·Pregnancy / breastfeeding
·Disrupted hypothalamic-pituitary axis

Relative Contraindications

Prostamax

·History of prostate cancer — theoretical concern re: transcriptional activation
·Undiagnosed prostatic nodules or elevated PSA

Sermorelin

·Untreated diabetes

05Administration Protocol

Parameter

Prostamax

Sermorelin

1. Route

Subcutaneous or intramuscular — per Khavinson bioregulator tradition. No published human pharmacokinetic data.

Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL = 250 mcg per 0.1 mL.

2. Reconstitution

If lyophilised: reconstitute with sterile water per manufacturer protocol (not standardized in literature).

SQ — abdomen or thigh. Rotate sites.

3. Frequency

Typically daily or every-other-day in Russian clinical tradition; duration 10–20 days per cycle.

Pre-sleep, fasted.

4. Monitoring

No established biomarkers. Theoretical: PSA, prostate imaging, symptom scores (IPSS for BPH).

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

5. Note

All protocols derived from non-peer-reviewed Russian clinical practice; Western regulatory approval absent.

29–31G, 4–8 mm insulin syringe.

06Stack Synergy

Prostamax

— no documented stacks

Sermorelin

+ Ipamorelin

Strong

View Ipamorelin →

Sermorelin (GHRH analogue) and ipamorelin (selective GHRP) form the prototypical GHRH+GHRP dual-axis stack at the lowest cost. Both peak within 30 min and produce a sharp physiological GH pulse without cortisol/prolactin elevation.

Sermorelin: 200–300 mcg SQ · pre-sleep
Ipamorelin: 200–300 mcg SQ · same injection
Primary benefit: Pulsatile GH stimulation, recovery, body composition

Raun 1998 Walker 1994